Compare MBBC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBBC | RNTX |
|---|---|---|
| Founded | 1902 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 35.5M |
| IPO Year | N/A | N/A |
| Metric | MBBC | RNTX |
|---|---|---|
| Price | $12.73 | $1.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 3.4K | ★ 191.1K |
| Earning Date | 02-22-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $7,299,708.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $111.00 | ★ N/A |
| Revenue Growth | ★ 7.77 | N/A |
| 52 Week Low | $8.74 | $1.02 |
| 52 Week High | $12.89 | $3.50 |
| Indicator | MBBC | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.26 | 67.87 |
| Support Level | $12.28 | $1.12 |
| Resistance Level | $12.87 | $1.25 |
| Average True Range (ATR) | 0.26 | 0.11 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 87.05 | 88.82 |
Marathon Bancorp Inc is a mid-tier holding company for Marathon Bank, a Wisconsin-chartered savings bank. The group operates as a community-oriented bank offering a variety of financial products and services to meet the needs of customers. The primary deposit products are demand deposits, savings, and certificates of deposits; and prime lending products are commercial real estate, commercial and industrial, construction, one-to-four-family residential, multifamily real estate, and consumer loans. The majority of the group's revenue comes from interest income on loans and debt securities.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.